Cancers de la peau - Clinique du mélanome - Etudes en cours

Contact : Karoline Amann

  • Phase III, open label, multicenter, two-arm, randomized study to investigate the efficacy and safety of cbimetinib plus atezolizumab vs. Pembrolizumab in patients with previously untreated advanced Braf wild type melanoma
Sponsor: Roche 
Principal Investigator: Prof. Jean-François Baurain
  • A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Sponsor: BMS
Principal Investigator: Prof. Jean-François Baurain
  • Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716) 
Sponsor: MSD 
Principal Investigator: Prof. Jean-François Baurain